PrecAIse

Expansion of precision oncology treatment of tumor patients by integrating focused protein analysis and personalized microtumor drug tests.

Description

Precision oncology presents practitioners with the challenge of adapting and interpreting clinical and imaging data, histological and molecular pathology results and genetic analyses to the individual patient. Targeted expansion using new technologies is required in order to identify and implement the best possible therapeutic approach for individual patients from large-volume data sets (big data). PRECAISE addresses this need by using focused protein analytics to detect phenotypic changes in signal transduction pathways in tumor cells. Patient-derived in vitro-generated microtumors are used for individualized testing, thus enabling personalized medication. The decision-making process of the multidisciplinary Molecular Tumor Board is supported by an AI-supported tool that documents the path of therapy definition by means of video transcription and makes it transparent for the treating physicians. In PRECAISE, innovative diagnostic methods are for the first time placed directly in the clinical context as a service offering and define an individualized and effective therapy for the patient.

 

Projectlead

Dr. Markus Templin

Group Leader Cellular & Molecular Biology